News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

4SC AG (VSC.F)'s Resminostat receives FDA Orphan Drug Status for Hodgkin's Lymphoma


9/26/2011 9:36:52 AM

PLANEGG-MARTINSRIED, Germany--(BUSINESS WIRE)--4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to 4SC's lead oncology compound resminostat in Hodgkin's lymphoma (HL). Resminostat was recently granted orphan drug designation by the FDA in another oncology indication, hepatocellular carcinoma (HCC).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES